Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) will host a conference call on May 6, 2021, at 4:30 PM ET, to discuss its Q1 2021 financial results and provide a business update. The conference will focus on Eiger's advancements in treatments for rare diseases, including Hepatitis Delta Virus and Hutchinson-Gilford Progeria Syndrome. Notably, Lonafarnib is in a global Phase 3 trial, while Peginterferon lambda is entering Phase 3. Zokinvy is the first FDA-approved product, with a Marketing Authorization Application under review in Europe.

Positive

• Lonafarnib is in a global Phase 3 trial, indicating strong progress in drug development.
• Peginterferon lambda is entering Phase 3, confirming ongoing advancements in their clinical pipeline.
• Zokinvy is the first FDA-approved product, showing successful commercialization efforts.

Negative

• None.

PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, May 6, 2021 at 4:30 PM Eastern Time to discuss its financial results and provide a business update for first quarter 2021.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.  The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Zokinvy^® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approved product.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). 

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:

Sri Ryali
Email: sryali@eigerbio.com
Phone: 1-650-272-6138

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-first-quarter-2021-financial-results-and-business-update-on-thursday-may-6-2021-301280002.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When will Eiger BioPharmaceuticals announce its Q1 2021 financial results?

Eiger BioPharmaceuticals will announce its Q1 2021 financial results during a conference call on May 6, 2021.

What are the key focuses of Eiger's clinical programs?

Eiger's key clinical programs focus on treatments for Hepatitis Delta Virus and Hutchinson-Gilford Progeria Syndrome.

What is the significance of Zokinvy for Eiger BioPharmaceuticals?

Zokinvy is significant as it is Eiger's first FDA-approved product, indicating successful product development.

How can I participate in the Eiger BioPharmaceuticals conference call?

To participate in the conference call, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.